Original research
by
Landis, Rachel K. et al
Release Date
2022
Geography
USA
Language of Resource
English
Full Text Available
No
Open Access / OK to Reproduce
No
Peer Reviewed
Yes
Objective
Buprenorphine is an effective medication for the treatment of opioid use disorder (OUD), but the association between prior authorization policies and quality of care for individuals receiving buprenorphine treatment is not well-understood.
Findings/Key points
Prior authorization policies were associated with lower likelihood of buprenorphine treatment of at least 180 days. Prior authorization policies may reduce duration of buprenorphine treatment episodes.
Design/methods
Medicaid data
Keywords
Policy/Regulatory
Substitution/OAT
